



(11)

**EP 3 488 443 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)  
Corrections, see  
Bibliography INID code(s) 73**

(51) Int Cl.:

**C12N 15/10<sup>(2006.01)</sup>**

(86) International application number:

**PCT/EP2017/068226**

(48) Corrigendum issued on:

**29.09.2021 Bulletin 2021/39**

(87) International publication number:

**WO 2018/015433 (25.01.2018 Gazette 2018/04)**

(45) Date of publication and mention  
of the grant of the patent:

**18.08.2021 Bulletin 2021/33**

(21) Application number: **17743311.7**

(22) Date of filing: **19.07.2017**

(54) **SELECTING NEOEPITOPES AS DISEASE-SPECIFIC TARGETS FOR THERAPY WITH  
ENHANCED EFFICACY**

AUSWAHL VON NEOEPITOPEN ALS KRANKHEITSSPEZIFISCHE ZIELE FÜR EINE THERAPIE  
MIT ERHÖHTER WIRKSAMKEIT

SÉLECTION DE NÉOÉPITOPES EN TANT QUE CIBLES SPÉCIFIQUES DE MALADIE POUR UN  
TRAITEMENT PRÉSENTANT UNE EFFICACITÉ ACCRUE

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO RS SE SI SK SM TR**

Designated Extension States:

**BA ME**

(74) Representative: **Schnappauf, Georg et al**

**ZSP Patentanwälte PartG mbB**

**Hansastraße 32**

**80686 München (DE)**

(30) Priority: **20.07.2016 PCT/EP2016/067348**

(56) References cited:

**WO-A1-2013/120509 WO-A2-2011/143656**

**WO-A2-2012/159754 US-A1- 2015 331 992**

(43) Date of publication of application:

**29.05.2019 Bulletin 2019/22**

- **TUERECI OEZLEM ET AL: "Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines", CLINICAL CANCER RESEARCH, vol. 22, no. 8, April 2016 (2016-04), pages 1885-1896, XP055300469, ISSN: 1078-0432**
- **CASTLE JOHN C ET AL: "Mutated tumor alleles are expressed according to their DNA frequency", SCIENTIFIC REPORTS, vol. 4, April 2014 (2014-04), pages 1-6, XP002774681, ISSN: 2045-2322**

(60) Divisional application:

**21178672.8**

(73) Proprietor: **BioNTech SE**

**55131 Mainz (DE)**

(72) Inventors:

- **TADMOR, Arbel D.  
55294 Bodenheim (DE)**
- **SAHIN, Ugur  
55116 Mainz (DE)**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 3 488 443 B8**

- |   |   |
|---|---|
| <ul style="list-style-type: none"> <li>• SCOTT L CARTER ET AL: "Absolute quantification of somatic DNA alterations in human cancer", NATURE BIOTECHNOLOGY, vol. 30, no. 5, 1 January 2012 (2012-01-01), pages 413-421, XP055042894, ISSN: 1087-0156, DOI: 10.1038/nbt.2203</li> <li>• MYHRE SIMEN ET AL: "Influence of DNA copy number and mRNA levels on the expression of breast cancer related proteins", MOLECULAR ONCOLOGY, vol. 7, no. 3, June 2013 (2013-06), pages 704-718, XP002777340, ISSN: 1574-7891</li> <li>• GUNNARSSON CECILIA ET AL: "Amplification of HSD17B1 has prognostic significance in postmenopausal breast cancer", BREAST CANCER RESEARCH AND TREATMENT, vol. 108, no. 1, March 2008 (2008-03), pages 35-41, XP002777341, ISSN: 0167-6806</li> </ul> | <ul style="list-style-type: none"> <li>• WANG TIM ET AL: "Identification and characterization of essential genes in the human genome", HHS Public Access Author Manuscript , November 2015 (2015-11), pages 1-13, XP002777395, Retrieved from the Internet: URL: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662922/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4662922/</a> [retrieved on 2018-01-18]</li> <li>• CHIARI RITA ET AL: "Two antigens recognized by autologous cytolytic T lymphocytes on a melanoma result from a single point mutation in an essential housekeeping gene", CANCER RESEARCH, vol. 59, no. 22, 15 November 1999 (1999-11-15), pages 5785-5792, XP055111371, ISSN: 0008-5472</li> </ul> |
|---|---|